Patents by Inventor Lothar Daum

Lothar Daum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
    Publication number: 20030161828
    Abstract: The present invention relates to the use of Tumor Necrosis Factor (TNF) antagonists in the treatment of patients with an inflammatory reaction and without suffering from total organ failure.
    Type: Application
    Filed: February 19, 2002
    Publication date: August 28, 2003
    Applicant: Abbott Gmbh & Co. KG
    Inventors: Heidrun Dorothea Abdelghany, William T. Barchuk, Lothar Daum, Jurgen Eiselstein, Martin Kaul, Lori L. Van Meter
  • Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
    Publication number: 20010010819
    Abstract: The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.
    Type: Application
    Filed: February 14, 2001
    Publication date: August 2, 2001
    Applicant: Knoll Aktiengesellschaft
    Inventors: Roswitha Stenzel, Martin Kaul, Lothar Daum, Joachim Kempeni, Christa Raab, Sibylle Schaefer
  • Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
    Patent number: 6235281
    Abstract: The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.
    Type: Grant
    Filed: August 7, 1996
    Date of Patent: May 22, 2001
    Assignee: Knoll Aktiengesellschaft
    Inventors: Roswitha Stenzel, Martin Kaul, Lothar Daum, Joachim Kempeni, Christa Raab, Sibylle Schaefer
  • Proteins and the preparation thereof
    Patent number: 5344915
    Abstract: Novel proteins which have a molecular weight of about 42,000 daltons and have at the N terminus the amino acid sequenceXaa Thr Pro Tyr Ala Pro Glu Pro Gly Set Thr Cys Arg Leu Arg Gluwhere X is hydrogen, a phenylalanine residue (Phe) or the amino acid sequences Ala Phe, Val Ala Phe, Gln Val Ala Phe, Ala Gln Val Ala Phe, Pro Ala Gln Val Ala Phe or Leu Pro Ala Gln Val Ala Phe, and which are suitable for the treatment of diseases, are described.
    Type: Grant
    Filed: September 26, 1991
    Date of Patent: September 6, 1994
    Assignee: BASF Aktiengesellschaft
    Inventors: Hans-Georg LeMaire, Heinz Hillen, Achim Moeller, Lothar Daum, Thomas Doerper, Thomas Subkowski
  • Proteins having a TNF action comprising TNF-fibromectin fusion protein
    Patent number: 5180811
    Abstract: Derivatives of a tumor necrosis factor (TNF), which originate from a modification at the amino terminus of the TNF molecule are suitable for controlling diseases.
    Type: Grant
    Filed: May 13, 1988
    Date of Patent: January 19, 1993
    Assignee: BASF Aktiengesellschaft
    Inventors: Thomas Doerper, Achim Moeller, Heinz Hillen, Gerhard Keilhauer, Franz Emling, Lothar Daum
  • N-terminal deletions of lymphotoxin, their preparation and use
    Patent number: 5157106
    Abstract: Polypeptides which differ from lymphotoxin by the absence of amino acids at the N-terminal end of the lymphotoxin are described. The polypeptides can be prepared by gene manipulation and are suitable, alone or in combination with lymphokines, as pharmaceuticals.
    Type: Grant
    Filed: June 15, 1987
    Date of Patent: October 20, 1992
    Assignee: BASF Aktiengesellschaft
    Inventors: Klaus Schollmeier, Achim Moeller, Wolfgang Koerwer, Thomas Doerper, Heinz Hillen, Lothar Daum, Franz Emling, Gerhard Keilhauer
  • Polysulfated heparins for treating diseases caused by retroviruses
    Patent number: 4966894
    Abstract: Polysulfated heparins are used for the preparation of drugs for the prophylaxis and therapy of diseases caused by retroviruses.
    Type: Grant
    Filed: December 22, 1988
    Date of Patent: October 30, 1990
    Assignee: BASF Aktiengesellschaft
    Inventors: Dieter Herr, Thomas Doerper, Lothar Daum, Karl-Heinz Geiss, Achim Moeller
  • Novel strobilurine derivatives, their preparation and their use
    Patent number: 4959484
    Abstract: Novel strobilurine derivatives which are suitable for the treatment of disorders and as fungicides are described.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: September 25, 1990
    Assignee: BASF Aktiengesellschaft
    Inventors: Lothar Daum, Gerhard Keilhauer, Gisela Lorenz, Eberhard Ammermann, Wolfgang Weber, Wolfgang Steglich, Bert Steffan, Angela Scherer